Richter's syndrome (RS), defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, is seen in about 2–10% of all CLL patients.1 The prognosis of RS is extremely poor with a median survival of about 6 months,2 although patients with clonally unrelated RS may have a better prognosis.1 No randomized controlled trials exist to date regarding therapeutic strategies in these patients. Data from phase I/II single-arm studies testing various therapeutic strategies have shown limited survival benefit with significant toxicity.2, 3, 4, 5, 6 Here, we present two cases of RS treated with a novel therapeutic agent, ibrutinib (Table 1).
Patient A was a 60-year-old male diagnosed with Rai stage IV CLL after evaluation of progressive lymphadenopathy. Fluorescence in situ hybridization (FISH) showed no deletion of ataxia telangiectasia mutated gene, chromosome 11q (ATM), chromosome 13q14.3, or p53. One month later, he developed rapidly progressive lymphadenopathy that upon biopsy revealed clonally related, activated B-cell type (ABC) diffuse large B-cell lymphoma (DLBCL) with a proliferating index Ki-67 of 50% consistent with RS. He was treated with cycles of rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP), rituximab/ifosfamide/carboplatin/etoposide (RICE) and rituximab/gemcitabine/oxaliplatin; however, his disease was refractory to these conventional therapeutic regimens. He was not a candidate for allogeneic hematopoietic stem cell transplantation due to a lack of insurance. Thus, the patient was started on ibrutinib. One month later, computed tomography (CT) scan revealed 70% regression of his disease, which improved at 3 months to 90% regression of disease.
Patient B was a 59-year-old male who was diagnosed with Rai stage III CLL after evaluation of anemia with lymphocytosis. He was observed for 8 years until he developed progressive lymphocytosis that required treatment of his CLL with bendamustine/rituximab and fludarabine/cyclophosphamide/rituximab. FISH showed trisomy 12 in 34% of nuclei and deletion of p53 in 40% of nuclei, but deletion of ATM and 13q14.3 were not detected. Subsequently, he developed fever, night sweats and rapidly progressing lymphadenopathy for which biopsy of his right neck lymphadenopathy revealed clonally related, ABC DLBCL with a proliferating index Ki-67 of 90% consistent with RS. He was treated with multiple cycles of R-CHOP and RICE. He had poor prognostic features, given his p53 deletion, high LDH level and bulky disease with lung nodular disease. His lymphoma was refractory to these conventional therapeutic regimens, and he was not a candidate for allogeneic hematopoietic stem cell transplantation due to a lack of insurance. Thus, he was started on ibrutinib. CT scan 2 months later showed 100% progression of his neck adenopathy. Ibrutinib was stopped after 3 months due to refractory disease.
Recent studies have shown that ibrutininb, a potent inhibitor of Bruton's tyrosine kinase receptor, is a viable therapeutic option in cases of relapsed/refactory CLL.7, 8 It remains unclear if this drug is effective against patients with RS as well. In an earlier phase Ib/II study on combination of ibrutinib with ofatumumab, a partial response was seen in two out of three patients with RS.9 It was not clear that whether these patients had different genetic profiles. In our case, both patients had ABC type DLBCL, which has been shown to have a better response to ibrutinib as compared with germinal center B-cell type DLBCL.10 However, patient A had an excellent response whereas patient B was refractory to ibrutinib therapy. In contrast to patient A, patient B had high-risk mutations (deletion of p53 and trisomy of chromosome 12) and a high-proliferation index (Ki-67 of 90%) suggesting a poor prognosis. This may suggest that ibrutinib is beneficial in a select group of patients with distinct genetic profiles. Our experience with these patients adds to a growing hypothesis that ibrutinib may be a viable therapeutic option in CLL patients with RS.
References
Parikh SA, Kay NE, Shanafelt TD . How we treat Richter syndrome. Blood 2014; 123: 1647–1657.
Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001; 42: 329–337.
Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003; 97: 1711–1720.
Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 2002; 43: 767–772.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 196–203.
Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013; 13: 568–574.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med 2014; 371: 213–223.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2013; 369: 32–42.
Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, AMaddocks KJ, Blum KA et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012; 30, suppl; abstract 6508.
Gerecitano JF, Goy A, De Vos S, Kenkre VP, Barr PM, Blum KA et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. American Society of Hematology, 8–11 December 2012; Atlanta, GA, USA 2012.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author Contributions
MGM compiled the patients treated; all authors wrote the manuscript and contributed to revisions.
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
About this article
Cite this article
Giri, S., Hahn, A., Yaghmour, G. et al. Ibrutinib has some activity in Richter’s syndrome. Blood Cancer Journal 5, e277 (2015). https://doi.org/10.1038/bcj.2014.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/bcj.2014.98
This article is cited by
-
Novel Approaches for the Treatment of Patients with Richter’s Syndrome
Current Treatment Options in Oncology (2022)
-
Richter Syndrome
Current Oncology Reports (2021)
-
Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies
Annals of Hematology (2018)
-
Richter Syndrome in Chronic Lymphocytic Leukemia
Current Hematologic Malignancy Reports (2016)